[Form 4] Revolution Medicines, Inc. Insider Trading Activity
Margaret A. Horn, Chief Operating Officer and Director of Revolution Medicines, reported a sale of 4,775 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. After the transaction she beneficially owns 145,900 shares, which the filing states includes 70,500 restricted stock units (RSUs). The sale was executed under a Rule 10b5-1 instruction letter adopted May 31, 2023, to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Horn on 09/18/2025.
Margaret A. Horn, Chief Operating Officer e Direttore di Revolution Medicines, ha riferito una vendita di 4.775 azioni ordinarie dell’emittente il 16/09/2025 a un prezzo riportato di 45,8249 dollari per azione. Dopo la transazione possiede in modo beneficiario 145.900 azioni, che la dichiarazione indica includere 70.500 unità azionarie vincolate (RSU). La vendita è stata eseguita secondo una lettera istruttoria della Rule 10b5-1 adottata il 31 maggio 2023, per soddisfare gli obblighi di ritenuta fiscale della persona che riporta al vesting delle RSU dopo il 15 luglio 2023. Il Form 4 è stato firmato da un procuratore-in-fact per conto della signora Horn il 18/09/2025.
Margaret A. Horn, Directora de Operaciones y Directora de Revolution Medicines, informó la venta de 4.775 acciones ordinarias del emisor el 16/09/2025 a un precio reportado de $45.8249 por acción. Tras la operación posee beneficialmente 145.900 acciones, que la declaración indica incluyen 70.500 unidades de acciones restringidas (RSU). La venta se ejecutó bajo una carta de instrucción de la Rule 10b5-1 adoptada el 31 de mayo de 2023, para satisfacer las obligaciones de retención de impuestos de la persona informante al vesting de RSU después del 15 de julio de 2023. El Formulario 4 fue firmado por un apoderado en nombre de la Sra. Horn el 18/09/2025.
Margaret A. Horn, 최고운영책임자(COO)이자 Revolution Medicines 이사의 발표로, 발행자의 보통주 4,775주를 2025년 9월 16일에 주당 보고가 $45.8249로 거래했다고 보고했습니다. 거래 후 그녀는 실질적으로 145,900주의 주식을 보유하고 있으며, 보고서에는 70,500주restricted stock units(RSUs)가 포함되어 있다고 명시되어 있습니다. 이 매도는 2023년 5월 31일에 채택된 Rule 10b5-1 지시 서신에 따라 RSU vesting(주식권 행사) 이후의 세금 원천징수 의무를 충족하기 위해 실행되었습니다. 4 Form은 2025년 9월 18일에 Horn 부인 behalf의 대리인이 서명했습니다.
Margaret A. Horn, Directrice des opérations et Administratrice chez Revolution Medicines, a annoncé la vente de 4 775 actions ordinaires de l’émetteur le 16/09/2025 à un prix déclaré de $45,8249 par action. Après la transaction, elle détient bénéficiairement 145 900 actions, ce que le dossier indique comme incluant 70 500 unités d’actions restreintes (RSU). La vente a été exécutée en vertu d’une lettre d’instruction Rule 10b5-1 adoptée le 31 mai 2023, pour satisfaire les obligations de retenue d’impôt de la personne qui déclare lors du vesting des RSU après le 15 juillet 2023. Le Form 4 a été signé par un mandataire au nom de Mme Horn le 18/09/2025.
Margaret A. Horn, Chief Operating Officer und Direktorin von Revolution Medicines, berichtete über den Verkauf von 4.775 Stammaktien des Emittenten am 16.09.2025 zu einem gemeldeten Preis von $45,8249 pro Aktie. Nach der Transaktion besitzt sie rechtlich ein Beneficial Ownership von 145.900 Aktien, wozu die Einreichung 70.500 Restricted Stock Units (RSUs) einschließt. Der Verkauf wurde gemäß einem Rule 10b5-1-Anweisungsbrief, der am 31. Mai 2023 angenommen wurde, durchgeführt, um die Steuerabzugsverpflichtungen der berichtspflichtigen Person beim Vesting der RSUs nach dem 15. Juli 2023 zu erfüllen. Das Form 4 wurde am 18.09.2025 von einem ausständigen Bevollmächtigten im Namen von Frau Horn unterzeichnet.
مارغريت أ. هورن، رئيسة التشغيل ومديرة Revolution Medicines، أفادت ببيع 4,775 سهماً عادياً للمصدر في 16/09/2025 بسعر مُبلّغ عنه قدره $45.8249 للسهم الواحد. وبعد الصفقة تملك بشكل مستفيد 145,900 سهماً، وهو ما تنص عليه الإفادة بأنه يتضمن 70,500 وحدة أسهم مقيدة (RSUs). تم تنفيذ البيع وفقاً لرسالة تعليمات Rule 10b5-1 المعتمدة في 31 مايو 2023 لتلبية التزامات الخصم من الضرائب الخاصة بالشخص المبلغ عند vesting RSU بعد 15 يوليو 2023. وتم توقيع نموذج 4 من قبل وكيل قانوني نيابة عن السيدة هورن في 18/09/2025.
Margaret A. Horn，Revolution Medicines 的首席运营官兼董事，报告在 2025/09/16 以每股 $45.8249 的价格出售发行人普通股 4,775 股。交易后她受益所有权为 145,900 股，文件中表示其中包含 70,500 股受限股票单位（RSU）。此次出售是根据于 2023/05/31 通过的 Rule 10b5-1 指示函执行，以满足在 2023/07/15 之后 RSU 授予时的税款代扣义务。Form 4 由代表 Horn 女士的代理人于 2025/09/18 签署。
- Transaction executed under a Rule 10b5-1 plan, indicating the sale was pre-planned and follows an established instruction letter
- Reporting shows transparency by disclosing the amount sold, price, remaining beneficial ownership, and that RSUs are included in holdings
- Reduction in beneficial ownership by 4,775 shares following the reported sale
- 70,500 RSUs are outstanding, which may result in future withholding or sales upon vesting
Insights
TL;DR: A routine insider sale under a 10b5-1 plan to cover tax withholding; not an unusual governance event.
The Form 4 documents a disposition of 4,775 shares at $45.8249 executed pursuant to a Rule 10b5-1 plan tied to RSU vesting. Such sales commonly reflect withholding or diversification needs rather than discretionary trading. The remaining beneficial ownership of 145,900 shares, including 70,500 RSUs, keeps the reporting person materially invested in the company while addressing tax obligations.
TL;DR: Use of an established 10b5-1 program indicates pre-planned, compliant handling of insider tax liabilities.
The filing clearly states the transaction was made under a 10b5-1 instruction adopted May 31, 2023, to satisfy tax withholding on RSU vesting. That transparency and advance planning reduce concerns about opportunistic insider selling. The Form 4 was properly executed by an attorney-in-fact and filed by one reporting person, reflecting standard procedural compliance.
Margaret A. Horn, Chief Operating Officer e Direttore di Revolution Medicines, ha riferito una vendita di 4.775 azioni ordinarie dell’emittente il 16/09/2025 a un prezzo riportato di 45,8249 dollari per azione. Dopo la transazione possiede in modo beneficiario 145.900 azioni, che la dichiarazione indica includere 70.500 unità azionarie vincolate (RSU). La vendita è stata eseguita secondo una lettera istruttoria della Rule 10b5-1 adottata il 31 maggio 2023, per soddisfare gli obblighi di ritenuta fiscale della persona che riporta al vesting delle RSU dopo il 15 luglio 2023. Il Form 4 è stato firmato da un procuratore-in-fact per conto della signora Horn il 18/09/2025.
Margaret A. Horn, Directora de Operaciones y Directora de Revolution Medicines, informó la venta de 4.775 acciones ordinarias del emisor el 16/09/2025 a un precio reportado de $45.8249 por acción. Tras la operación posee beneficialmente 145.900 acciones, que la declaración indica incluyen 70.500 unidades de acciones restringidas (RSU). La venta se ejecutó bajo una carta de instrucción de la Rule 10b5-1 adoptada el 31 de mayo de 2023, para satisfacer las obligaciones de retención de impuestos de la persona informante al vesting de RSU después del 15 de julio de 2023. El Formulario 4 fue firmado por un apoderado en nombre de la Sra. Horn el 18/09/2025.
Margaret A. Horn, 최고운영책임자(COO)이자 Revolution Medicines 이사의 발표로, 발행자의 보통주 4,775주를 2025년 9월 16일에 주당 보고가 $45.8249로 거래했다고 보고했습니다. 거래 후 그녀는 실질적으로 145,900주의 주식을 보유하고 있으며, 보고서에는 70,500주restricted stock units(RSUs)가 포함되어 있다고 명시되어 있습니다. 이 매도는 2023년 5월 31일에 채택된 Rule 10b5-1 지시 서신에 따라 RSU vesting(주식권 행사) 이후의 세금 원천징수 의무를 충족하기 위해 실행되었습니다. 4 Form은 2025년 9월 18일에 Horn 부인 behalf의 대리인이 서명했습니다.
Margaret A. Horn, Directrice des opérations et Administratrice chez Revolution Medicines, a annoncé la vente de 4 775 actions ordinaires de l’émetteur le 16/09/2025 à un prix déclaré de $45,8249 par action. Après la transaction, elle détient bénéficiairement 145 900 actions, ce que le dossier indique comme incluant 70 500 unités d’actions restreintes (RSU). La vente a été exécutée en vertu d’une lettre d’instruction Rule 10b5-1 adoptée le 31 mai 2023, pour satisfaire les obligations de retenue d’impôt de la personne qui déclare lors du vesting des RSU après le 15 juillet 2023. Le Form 4 a été signé par un mandataire au nom de Mme Horn le 18/09/2025.
Margaret A. Horn, Chief Operating Officer und Direktorin von Revolution Medicines, berichtete über den Verkauf von 4.775 Stammaktien des Emittenten am 16.09.2025 zu einem gemeldeten Preis von $45,8249 pro Aktie. Nach der Transaktion besitzt sie rechtlich ein Beneficial Ownership von 145.900 Aktien, wozu die Einreichung 70.500 Restricted Stock Units (RSUs) einschließt. Der Verkauf wurde gemäß einem Rule 10b5-1-Anweisungsbrief, der am 31. Mai 2023 angenommen wurde, durchgeführt, um die Steuerabzugsverpflichtungen der berichtspflichtigen Person beim Vesting der RSUs nach dem 15. Juli 2023 zu erfüllen. Das Form 4 wurde am 18.09.2025 von einem ausständigen Bevollmächtigten im Namen von Frau Horn unterzeichnet.
FAQ
What did Margaret Horn report on Form 4 for Revolution Medicines (RVMD/RVMDW)?
Why was the sale executed under a Rule 10b5-1 plan?
How many restricted stock units (RSUs) does the filing disclose?
Who signed the Form 4 filing and when?
Was this Form 4 filed by one reporting person or jointly?
